Maria Emanuela D.
- Country
- Italy
- Department
- U.O.D. of Gastroenterology
Research Overview
- Efficacy and Safety of Upadacitinib in Maintenance and Long-Term Extension for Crohn's Disease Post-Induction Responders
- Efficacy and Safety of Risankizumab as Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis: A Randomized, Double-Blind, Placebo-Controlled Study
- Evaluation of Rosnilimab Efficacy and Safety in Moderate to Severe Ulcerative Colitis: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study
Data & Insights
Has run more than one trial at 77 of 225 partner sites.
Specializations
Inflammatory Bowel Disease Treatment
The investigator specializes in researching innovative therapies for inflammatory bowel disease, with particular emphasis on both ulcerative colitis and Crohn's disease.
- Advanced therapeutic approaches for moderate to severe cases
- Long-term disease management strategies
- Novel treatment evaluation
Their work encompasses comprehensive assessment of emerging therapeutic options for inflammatory bowel conditions.
Ulcerative Colitis Expertise
Focused investigation into moderately to severely active ulcerative colitis treatment approaches, including evaluation of novel therapeutic agents such as etrasimod and rosnilimab.
- Treatment efficacy assessment
- Long-term safety monitoring
- Clinical response evaluation
The research extends to maintenance therapy protocols and long-term disease management strategies.
Crohn's Disease Research
Extensive work in Crohn's disease management, investigating therapeutic agents including upadacitinib, risankizumab, and etrasimod.
- Induction therapy optimization
- Maintenance treatment protocols
- Long-term therapeutic outcomes
Their research encompasses both immediate disease control and sustained therapeutic approaches.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.